F-4077 Fenretinide, >99%

Synonyms : [4-HPR] [MK-4016] [McN-R-1967] [RII retinamide] [Ro 22-4667]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 39
  • 32
  • 28
  • 4,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 64
  • 53
  • 47
  • 7,100
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 89
  • 74
  • 65
  • 9,900
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 121
  • 101
  • 89
  • 13,400
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 233
  • 194
  • 171
  • 25,800
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 335
  • 280
  • 246
  • 37,100
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 545
  • 455
  • 401
  • 60,400
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 915
  • 764
  • 673
  • 101,500
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 1,990
  • 1,663
  • 1,464
  • 220,700
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 391.55
  • C26H33NO2
  • [65646-68-6]
  • M.I. 15: 4025

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 90 mg/mL; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-5 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Certificate of Analysis

  • Fenretinide is a vitamin A analogue and has been used as a chemopreventive retinoid for women at risk of developing contralateral breast cancer. Fenretinide treatment resulted in a significant risk reduction of second breast cancer in premenopausal women after 15 year followups, which is remarkable at younger ages, and persisted several years after treatment cessation. Veronesi, U., et al. "Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer." Ann. Oncol. 17: 1065-1071 (2006).
  • Fenretinide is concentrated by breast tissue in patients. Mehta, R.G., et al. "Distribution of fenretinide in the mammary gland of breast cancer patients." Eur. J. Cancer 27: 138-141 (1991).
  • The mechanism of action for fenretinide is not yet fully understood. It may inhibit cell growth through induction of apoptosis, not differentiation, and through vitamin A receptor-dependent and -independent mechanisms. Cazzaniga, M., et al. "Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?" J. Biomed. Biotechnol. 2012: 172897 (2012).
  • Another CAS number previously assigned to Fenretinide, namely 1006055-28-2, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
390